ARQT Overview

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.

Wall Street analysts forecast ARQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is32.00 USD with a low forecast of 30.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Arcutis Biotherapeutics Inc revenue for the last quarter amounts to 105.40M USD, increased 60.07

Arcutis Biotherapeutics Inc. EPS for the last quarter amounts to -0.09 USD, decreased -55.00

Arcutis Biotherapeutics Inc (ARQT) has 354 emplpoyees as of May 09 2026.

Today ARQT has the market capitalization of 2.65B USD.